abs

학술발표회초록보기

초록문의 abstract@kcsnet.or.kr

결제문의 member@kcsnet.or.kr

현재 가능한 작업은 아래와 같습니다.
  • 08월 28일 16시 이후 : 초록수정 불가능, 일정확인 및 검색만 가능

Dual effect of ARSA on the inhibition of osteoclastogenesis and bone resorption

등록일
2008년 8월 6일 12시 15분 30초
접수번호
0188
발표코드
33P165포 이곳을 클릭하시면 발표코드에 대한 설명을 보실 수 있습니다.
발표시간
목 <발표Ⅰ>
발표형식
포스터
발표분야
생명화학
저자 및
공동저자
김명희, 김영섭1, 민용기2, 김성환3
충남대학교 생화학과, Korea
1한국화학연구원 신약연구단, Korea
2한국화학연구원 생명화학연구단, Korea
3한국화학연구원 화학유전체 연구실, Korea
With the fact that the development of anti-resorptive agents from natural substances has gained more interest in the treatment of osteoporosis, here, 222 natural compounds were evaluated whether they have a potential to suppress RANKL-induced osteoclastogenesis in RAW264.7 cells. Of these compounds, ARSA significantly inhibited the RANKL-induced TRAP activity and formation of multinucleated osteoclast in a dose-dependent manner. In addition, it was shown to attenuate the RANKL-induced transcript levels of osteoclast specific genes, which have been known to be highly expressed in the process of osteoclastogenesis. Interestingly, ARSA was shown to inhibit the RANKL-induced activation of mitogen-activated protein kinase and NF-kappaB. The mRNA induction of AP-1 (especially, Fra-2) and NFATc1 by RANKL was also significantly prevented by ARSA. The inhibitory effect of ARSA on mouse bone marrow-derived osteoclastogenesis was also observed. Additionally, in mature osteoclasts, ARSA suppressed the bone resorption by inducing the osteoclast apoptosis with the activation of caspase 3 and 9. In conclusion, ARSA was shown to be with the dual activity; it inhibited the formation of osteoclast and the bone resorptive activity of mature osteoclasts and it suggested that ARSA could be useful to develop the therapeutic agents for osteoporosis.

상단으로